Quick Take
Akero Therapeutics (AKRO) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steatohepatitis [NASH].
AKRO has demonstrated very promising trial results for its lead candidate and the IPO funds will likely last the firm through 2022.
Company & Technology
San Francisco, California-based Akero was founded in 2017 to develop a therapy for the treatment of NASH, a serious type of